Navigation Links
SanBio Announces Site Opening of Phase 1/2a Clinical Trial of Novel Cell Therapy in Stable Stroke Patients at University of Pittsburgh Medical Center
Date:9/20/2011

MOUNTAIN VIEW, Calif., Sept. 20, 2011 /PRNewswire/ -- SanBio, Inc., a leader in cell therapies for regenerative medicine, has announced the site initiation and opening of a Phase 1/2a clinical trial testing a novel cell therapy product, SB623, in patients suffering from disability resulting from ischemic stroke. The study is taking place at the University of Pittsburgh Medical Center. An additional study site is also open and recruiting patients at the Stanford University Medical Center in Palo Alto, CA.

SB623 has been shown to improve neurological behavior in preclinical models of stroke. In this study, safety and efficacy parameters will be evaluated, including improvements in motor function and cognitive status. The trial will evaluate 18 patients who have suffered an ischemic stroke within the past six to 24 months and have a motor neurological deficit.

"We are excited to be a part of this important new study offering a novel approach to therapy for patients suffering from ischemic stroke disability," said Douglas Kondziolka, MD, Peter J. Jannetta professor and vice chairman of neurological surgery at the University of Pittsburgh Medical Center (UPMC), and Principal Investigator of the study.

"Preclinical models have shown that SB623 restores function in animal models of stroke. With over seven million stroke victims in the U.S. today, we are eager to explore the potential of SB623 in patients who may otherwise be permanently disabled," said Lawrence Wechsler, MD, chair, department of neurology at UPMC.

"With two trial sites now open, our goal is to explore the potential of SB623 as a potential treatment for stroke disability as rapidly as possible," said Keita Mori, Co-CEO of SanBio. "SB623 represents a significant step forward in the development of regenerative therapies."

For more information on the SB623 trial, please visit www.strokeclinicaltrial.org.

About
'/>"/>

SOURCE SanBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dainippon Sumitomo Pharma and SanBio Collaborate on Cell Therapy for Stroke Recovery
2. Stanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability
3. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
4. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
5. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
6. Anesiva Announces Second Quarter 2008 Financial Results and Update
7. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
8. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
9. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. ThirdBiotech Announces Kemeta as Newest Sponsor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... (PRWEB) May 21, 2013 Many have ... as contributor to acne. Recently physicians from Clinical ... mental stress on the skin, and suggested using ... reduce the chemicals produced from stress that cause acne. ... the negative feelings acne brings about, stress causes changes ...
(Date:5/21/2013)... , May 21, 2013  Personal Genome Diagnostics ... its proprietary methodologies and expertise in genomic analysis ... targets in collaboration with Blueprint Medicines.  PGDx is ... identifying genomic alterations in tumors, and Blueprint Medicines ... inhibitors for a genetically defined patient population. ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Inflamax ... of the ITN to design the study, which ... two key clinical models used in the study ... and Nasal Allergen Challenge (NAC) models. Although both ... numerous publications, to date no direct comparison between ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 PathoGenetix, Inc., ... bacterial strain typing, announced today that it has successfully ... E. coli strains obtained from the Centers for Disease ... Scanning™ (GSS™) technology. The findings are detailed in a ... the American Society for Microbiology in Denver on Monday. ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3
... 5, 2011 Spherix Incorporated (Nasdaq: SPEX ... metabolic syndrome and atherosclerosis; and providers of technical and ... companies, today announced that its President, Dr. Robert Lodder, ... Biotech Showcase 2011. Dr. Lodder will deliver ...
... Mass., Jan. 5, 2011 Verenium Corporation (Nasdaq: ... commercialization of high-performance industrial enzyme solutions, today announced that ... will present at the upcoming Piper Jaffray Sixth Annual ... to begin at 3:00 p.m. EST on Wednesday, January ...
... N.Y. An entirely new type of nanomaterial developed ... of high-power rechargeable lithium (Li)-ion batteries for electric automobiles, ... and other portable devices. The new material, dubbed ... a scoop of ice cream on top, can withstand ...
Cached Biology Technology:Spherix to Present at Two Upcoming Prominent Finance Conferences 2Spherix to Present at Two Upcoming Prominent Finance Conferences 3Verenium to Present at Piper Jaffray Sixth Annual Clean Technology & Renewables Conference 2Verenium to Present at Piper Jaffray Sixth Annual Clean Technology & Renewables Conference 3'Nanoscoops' could spark new generation of electric automobile batteries 2'Nanoscoops' could spark new generation of electric automobile batteries 3
(Date:5/18/2013)... Research presented today at Digestive Disease Week (DDW) ... about the impact of coffee on autoimmune disease and ... consumption recently has been associated with reduced risk of ... more cups of java each month also correlate with ... at the Mayo Clinic, Rochester, MN, linked coffee consumption ...
(Date:5/17/2013)... 2013) The AGA Research Foundation announced a new ... between the gut microbiota, one of today,s most exciting ... , The AGA Research Awards Panel selected Andrew T. ... Hospital and Harvard Medical School, Boston, as the 2013 ... will receive $25,000 of funding, commencing in July 2013, ...
(Date:5/17/2013)... celebrate the science and technology of the region ... the inaugural Atlanta Science Festival, March 22-29, 2014. ... corporations, K-12 schools and universities, the festival will ... and adults at venues across the city. Learn ... annual Atlanta Science Festival is a collaboration of ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2First Atlanta Science Festival set for 2014 2
... rapidly spreading amphibian disease, has reached a site near ... the entire mountainous neotropics to be free of the ... Rescue and Conservation Project, a consortium of nine U.S. ... of frogs in imminent danger of extinction. ...
... America struggles down the road toward a coherent energy ... policymakers face numerous issues and realities. These include: the ... feasibility and costs to implement a widespread switch to ... consumers, preferences for particular types of power generation. ...
... to Research Careers) Program has announced the travel award ... Course in Immunology at The University of Minnesota in ... These awards are meant to promote the entry of ... of the basic science community and to encourage the ...
Cached Biology News:Scientists find deadly amphibian disease in the last disease-free region of central America 2Scientists find deadly amphibian disease in the last disease-free region of central America 3The energy debate: Coal vs. nuclear 2The energy debate: Coal vs. nuclear 3
... reagent for Virus isolation ... unique water insoluble Elastomeric ... and chaotropes; Engineered to ... viruses while preserving infectivity; ...
PKA Sampler Kit 10 mu g each...
Rabbit polyclonal to BCA1 ( Abpromise for all tested applications). Antigen: Generated using E.coli expressed mouse BCA1. Entrez GeneID: 10563 SWISS Protein ID: O43927...
Protein Tyrosine Phosphatase Sampler Kit 10g each...
Biology Products: